Monday, 29 June 2015

Fetzima (Major Depressive Disorder) Market Size Estimate By 2023: Radiant Insights, Inc.


Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.  

Fetzima (levomilnacipran) is an SNRI indicated for the treatment of MDD and is only available in the US. It gained FDA approval in July 2013 and was launched in December 2013. The product was developed by Forest (Actavis) following a partnership with Pierre Fabre. 

Read Complete Report with TOC: 

According to this agreement, Forest Laboratories is responsible for the clinical development and commercialization of Fetzima in the US and Canada, while Pierre Fabre is responsible for manufacturing and supplying the active pharmaceutical ingredient.  


- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. 
- Detailed information on Fetzima including product description, safety and efficacy profiles as well as a SWOT analysis. 
- Sales forecast for Fetzima for the US from 2013 to 2023. 
- Sales information covered for the US.  

Reasons to buy  

- Understand and capitalize by identifying products that are most likely to ensure a robust return 
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential 
- Make more informed business decisions from insightful and in-depth analysis of Fetzima performance 
- Obtain sales forecast for Fetzima from 2013-2023 in the US.

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. 

For More Information Visit – Radiant Insights

Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519

No comments:

Post a Comment